ATE248145T1 - Succinimid und maleimid cytokin-inhibitoren - Google Patents

Succinimid und maleimid cytokin-inhibitoren

Info

Publication number: ATE248145T1
Authority: AT; Austria
Prior art keywords: succinimide; cytokine inhibitors; maleimide; inhibitors; maleimide cytokine
Prior art date: 1995-10-06

Application number

AT96936155T

Other languages

English (en)

Inventor

George W Muller

Mary Shire

Original Assignee

Celgene Corp

George W Muller

Mary Shire

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-10-06

Filing date

1996-10-04

Publication date

2003-09-15

1996-10-04 Application filed by Celgene Corp, George W Muller, Mary Shire filed Critical Celgene Corp

2003-09-15 Application granted granted Critical

2003-09-15 Publication of ATE248145T1 publication Critical patent/ATE248145T1/de

Links

KZNICNPSHKQLFF-UHFFFAOYSA-N succinimide Chemical compound O=C1CCC(=O)N1 KZNICNPSHKQLFF-UHFFFAOYSA-N 0.000 title abstract 3
239000003112 inhibitor Substances 0.000 title abstract 2
102000004127 Cytokines Human genes 0.000 title 1
108090000695 Cytokines Proteins 0.000 title 1
PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 title 1
229960002317 succinimide Drugs 0.000 title 1
150000003923 2,5-pyrrolediones Chemical class 0.000 abstract 1
206010006895 Cachexia Diseases 0.000 abstract 1
206010014824 Endotoxic shock Diseases 0.000 abstract 1
102000004861 Phosphoric Diester Hydrolases Human genes 0.000 abstract 1
108090001050 Phosphoric Diester Hydrolases Proteins 0.000 abstract 1
XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 abstract 1
206010040070 Septic Shock Diseases 0.000 abstract 1
108060008682 Tumor Necrosis Factor Proteins 0.000 abstract 1
102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 abstract 1
208000006673 asthma Diseases 0.000 abstract 1
230000004968 inflammatory condition Effects 0.000 abstract 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
230000010076 replication Effects 0.000 abstract 1
241001430294 unidentified retrovirus Species 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/36—Oxygen or sulfur atoms
- C07D207/40—2,5-Pyrrolidine-diones
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/36—Oxygen or sulfur atoms
- C07D207/40—2,5-Pyrrolidine-diones
- C07D207/404—2,5-Pyrrolidine-diones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms, e.g. succinimide
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/44—Iso-indoles; Hydrogenated iso-indoles
- C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Oncology (AREA)
Virology (AREA)
Communicable Diseases (AREA)
Pulmonology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Molecular Biology (AREA)
Rheumatology (AREA)
Pain & Pain Management (AREA)
Transplantation (AREA)
Tropical Medicine & Parasitology (AREA)
AIDS & HIV (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pyrrole Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

AT96936155T 1995-10-06 1996-10-04 Succinimid und maleimid cytokin-inhibitoren ATE248145T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US08/539,879 US5658940A (en)	1995-10-06	1995-10-06	Succinimide and maleimide cytokine inhibitors
PCT/US1996/015864 WO1997012859A1 (en)	1995-10-06	1996-10-04	Succinimide and maleimide cytokine inhibitors

Publications (1)

Publication Number	Publication Date
ATE248145T1 true ATE248145T1 (de)	2003-09-15

Family

ID=24153040

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT96936155T ATE248145T1 (de)	1995-10-06	1996-10-04	Succinimid und maleimid cytokin-inhibitoren

Country Status (18)

Country	Link
US (1)	US5658940A (de)
EP (1)	EP0862552B1 (de)
JP (1)	JP3226546B2 (de)
KR (1)	KR100345826B1 (de)
AT (1)	ATE248145T1 (de)
AU (1)	AU723915B2 (de)
CA (1)	CA2233975C (de)
CZ (1)	CZ105398A3 (de)
DE (1)	DE69629716T2 (de)
ES (1)	ES2206600T3 (de)
FI (1)	FI119690B (de)
HU (1)	HUP9902034A3 (de)
NZ (1)	NZ321001A (de)
PL (1)	PL326063A1 (de)
PT (1)	PT862552E (de)
RU (1)	RU2176242C2 (de)
SK (1)	SK44698A3 (de)
WO (1)	WO1997012859A1 (de)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5801195A (en)	1994-12-30	1998-09-01	Celgene Corporation	Immunotherapeutic aryl amides
US6429221B1 (en) *	1994-12-30	2002-08-06	Celgene Corporation	Substituted imides
US5635517B1 (en) *	1996-07-24	1999-06-29	Celgene Corp	Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines
US6281230B1 (en)	1996-07-24	2001-08-28	Celgene Corporation	Isoindolines, method of use, and pharmaceutical compositions
FI990180A7 (fi) *	1996-08-12	1999-03-08	Celgene Corp	Uusia immunoterapeuttisia aineita ja niiden käyttö sytokiini-tasojen pienentämiseksi
US6020358A (en) *	1998-10-30	2000-02-01	Celgene Corporation	Substituted phenethylsulfones and method of reducing TNFα levels
AU2006200033B8 (en) *	1998-10-30	2008-09-11	Celgene Corporation	Substituted phenethylsulfones and methods of reducing TNF-alpha levels
US7629360B2 (en) *	1999-05-07	2009-12-08	Celgene Corporation	Methods for the treatment of cachexia and graft v. host disease
CA2379676A1 (en) *	1999-07-15	2001-01-25	Cytoclonal Pharmaceutics, Inc.	Method of designing tubulin polymerization stabilizers
US7122666B2 (en) *	1999-07-21	2006-10-17	Sankyo Company, Limited	Heteroaryl-substituted pyrrole derivatives, their preparation and their therapeutic uses
US6667316B1 (en)	1999-11-12	2003-12-23	Celgene Corporation	Pharmaceutically active isoindoline derivatives
US7182953B2 (en)	1999-12-15	2007-02-27	Celgene Corporation	Methods and compositions for the prevention and treatment of atherosclerosis restenosis and related disorders
US6326388B1 (en)	1999-12-21	2001-12-04	Celgene Corporation	Substituted 1,3,4-oxadiazoles and a method of reducing TNF-alpha level
US6699899B1 (en) *	1999-12-21	2004-03-02	Celgene Corporation	Substituted acylhydroxamic acids and method of reducing TNFα levels
US20010051348A1 (en) *	2000-01-28	2001-12-13	Lee Chee Wee	Novel ligands and methods for preparing same
US8030343B2 (en) *	2000-06-08	2011-10-04	Celgene Corporation	Pharmaceutically active isoindoline derivatives
US7091353B2 (en)	2000-12-27	2006-08-15	Celgene Corporation	Isoindole-imide compounds, compositions, and uses thereof
US7491634B2 (en) *	2006-04-28	2009-02-17	Asm International N.V.	Methods for forming roughened surfaces and applications thereof
GB0125658D0 (en) *	2001-10-25	2001-12-19	Ssl Int Plc	Medicaments
US7276529B2 (en) *	2002-03-20	2007-10-02	Celgene Corporation	Methods of the treatment or prevention of exercise-induced asthma using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
US6962940B2 (en)	2002-03-20	2005-11-08	Celgene Corporation	(+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
US7208516B2 (en) *	2002-03-20	2007-04-24	Celgene Corporation	Methods of the treatment of psoriatic arthritis using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
US7893101B2 (en)	2002-03-20	2011-02-22	Celgene Corporation	Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
US7498171B2 (en) *	2002-04-12	2009-03-03	Anthrogenesis Corporation	Modulation of stem and progenitor cell differentiation, assays, and uses thereof
CN1658848A (zh) *	2002-04-12	2005-08-24	细胞基因公司	血管生成调节剂的鉴定方法,由此发现的化合物和使用该化合物的治疗方法
CA2481385A1 (en) *	2002-04-12	2003-10-23	Celgene Corporation	Modulation of stem and progenitor cell differentiation, assays, and uses thereof
US20100129363A1 (en) *	2002-05-17	2010-05-27	Zeldis Jerome B	Methods and compositions using pde4 inhibitors for the treatment and management of cancers
EP1556033A4 (de) *	2002-05-17	2006-05-31	Celgene Corp	Verfahren und zusammensetzungen mit selektiven cytokin-hemmenden arzneimitteln zur behandlung und versorgung von krebs und anderen erkrankungen
HRP20050198A2 (hr) *	2002-08-10	2006-04-30	Altana Pharma Ag	Piperidin-piridazoni i ftalazoni kao inhibitori pde4
US6774758B2 (en) *	2002-09-11	2004-08-10	Kalyan P. Gokhale	Low harmonic rectifier circuit
MXPA05003889A (es) *	2002-10-15	2005-06-22	Celgene Corp	Farmacos inhibidores de citosina selectiva para tratar sindrome mielodisplastico.
US20040087558A1 (en)	2002-10-24	2004-05-06	Zeldis Jerome B.	Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment, modification and management of pain
US7776907B2 (en) *	2002-10-31	2010-08-17	Celgene Corporation	Methods for the treatment and management of macular degeneration using cyclopropyl-N-{2-[(1S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-3-oxoisoindoline-4-yl}carboxamide
BR0316002A (pt) *	2002-11-06	2005-09-13	Celgene Corp	Métodos de tratar ou prevenir e controlar uma doença mieloproliferativa, de reduzir ou evitar de um efeito adverso associado com a administração de um segundo agente ativo em um paciente sofrendo de uma doença mieloproliferativa e de aumentar a eficácia terapêutica de um tratamento de doença mieloproliferativa, composição farmacêutica e kit
WO2004043378A2 (en)	2002-11-06	2004-05-27	Celgene Corporation	Methods and compositions using selective cytokine inhibitory drugs for treatment and management of cancers and other diseases
KR20050075435A (ko) *	2002-11-18	2005-07-20	셀진 코포레이션	(＋)-３-(３,４-디메톡시-페닐)-３-(１-옥소-１,３-디히드로-이소인돌-２-일)-프로피온아미드의 사용 방법 및 그를포함하는 조성물
CA2506442A1 (en) *	2002-11-18	2004-07-01	Celgene Corporation	Methods of using and compositions comprising (-)-3-(3,4-dimethoxy-phenyl)-3-(1-oxo-1,3-dihydro-isoindol-2-yl)-propionamide
US20050187278A1 (en) *	2003-08-28	2005-08-25	Pharmacia Corporation	Treatment or prevention of vascular disorders with Cox-2 inhibitors in combination with cyclic AMP-specific phosphodiesterase inhibitors
US20050142104A1 (en) *	2003-11-06	2005-06-30	Zeldis Jerome B.	Methods of using and compositions comprising PDE4 modulators for the treatment and management of asbestos-related diseases and disorders
EP1692128A1 (de)	2003-11-19	2006-08-23	Signal Pharmaceuticals LLC	Indazolverbindungen und verfahren zu deren anwendung als proteinkinaseinhibitoren
US20080213213A1 (en) *	2004-04-14	2008-09-04	Zeldis Jerome B	Method For the Treatment of Myelodysplastic Syndromes Using (+)-2-[1-(3-Ethoxy-4-Methoxyphenyl)-2-Methylsulfonylethyl]-4-Acetylaminoisoindoline-1,3-Dione
CA2563377A1 (en) *	2004-04-23	2005-11-03	Celgene Corporation	Methods of using and compositions comprising pde4 modulators for the treatment and management of pulmonary hypertension
US7244759B2 (en) *	2004-07-28	2007-07-17	Celgene Corporation	Isoindoline compounds and methods of making and using the same
US20070190070A1 (en) *	2004-09-03	2007-08-16	Zeldis Jerome B	Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of disorders of the central nervous system
EP1811992A2 (de) *	2004-10-28	2007-08-01	Celgene Corporation	Verfahren und zusammensetzungen unter verwendung von pde4-modulatoren zur behandlung und versorgung von verletzungen des zentralen nervensystems
US20080138295A1 (en) *	2005-09-12	2008-06-12	Celgene Coporation	Bechet's disease using cyclopropyl-N-carboxamide
US20090318515A1 (en) *	2005-11-21	2009-12-24	Mordechai Sharir	Succinimide derivatives as ocular hypotensive agents
US8853257B2 (en)	2005-11-21	2014-10-07	Mordechai Sharir	Succinimide derivatives as ocular hypotensive agents
US20070155791A1 (en) *	2005-12-29	2007-07-05	Zeldis Jerome B	Methods for treating cutaneous lupus using aminoisoindoline compounds
NZ582096A (en) *	2007-06-29	2012-05-25	Gilead Sciences Inc	Antiviral compounds that inhibit hepatitis c virus (hcv)
WO2009120296A1 (en) *	2008-03-24	2009-10-01	Celgene Corporation	Treatment of psoriasis or psoriatic arthritis using cyclopropyl-n-{2-{(1s)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-3-oxoisoindoline-4-yl}carboxamide
US8092822B2 (en) *	2008-09-29	2012-01-10	Abbott Cardiovascular Systems Inc.	Coatings including dexamethasone derivatives and analogs and olimus drugs
MY160002A (en)	2009-02-10	2017-02-15	Celgene Corp	Methods of using and compositions comprising pde4 modulators for treatment, prevention and management of tuberculosis
WO2011127019A2 (en)	2010-04-07	2011-10-13	Celgene Corporation	Methods for treating respiratory viral infection
JP2013531499A (ja)	2010-06-15	2013-08-08	セルジーンコーポレイション	乾癬の治療のためのバイオマーカー
CN103788076B (zh) *	2014-01-22	2015-06-03	山西大学	一种检测半胱氨酸的试剂和方法
EP3142663A1 (de)	2014-05-16	2017-03-22	Celgene Corporation	Zusammensetzungen und verfahren zur behandlung von arteriosklerotischen herz-kreislauf-erkrankungen mit pde4-modulatoren
WO2015200177A1 (en)	2014-06-23	2015-12-30	Celgene Corporation	Apremilast for the treatment of a liver disease or a liver function abnormality
WO2017070291A1 (en)	2015-10-21	2017-04-27	Celgene Corporation	Pde4 modulators for treating and preventing immune reconstitution inflammatory syndrome (iris)
KR20190013786A (ko) *	2016-06-03	2019-02-11	제이엔씨 주식회사	중합성 극성 화합물, 액정 조성물 및 액정 표시 소자

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US2852526A (en) *	1955-05-03	1958-09-16	Schering Corp	Substituted pyrrolidines
GB1539817A (en) *	1976-10-22	1979-02-07	Ucb Sa	N-substituted lactams
FR2418790A1 (fr) *	1978-03-02	1979-09-28	Philagro Sa	Nouveaux derives de pyrrolidinone-2 et compositions herbicides les contenant
US4394369A (en) *	1982-05-24	1983-07-19	Fmc Corporation	Hydrogen peroxide process
US4996199A (en) *	1988-04-08	1991-02-26	Whitby Research, Inc.	Penetration enhancers for transdermal delivery of systemic agents
GB9013142D0 (en) *	1990-06-13	1990-08-01	Ciba Geigy Ag	Chemical compounds useful as metal deactivators
AU1531492A (en) *	1991-02-14	1992-09-15	Rockefeller University, The	Method for controlling abnormal concentration tnf alpha in human tissues
PT100441A (pt) *	1991-05-02	1993-09-30	Smithkline Beecham Corp	Pirrolidinonas, seu processo de preparacao, composicoes farmaceuticas que as contem e uso
US5204366A (en) *	1991-06-10	1993-04-20	American Cyanamid Company	2,5-dioxo-3-pyrroline-1-acetanilide fungicidal agents, compositions and method for use thereof
US5463063A (en) *	1993-07-02	1995-10-31	Celgene Corporation	Ring closure of N-phthaloylglutamines
WO1996020705A1 (en) *	1994-12-30	1996-07-11	Celgene Corporation	IMMUNOTHERAPEUTIC IMIDES/AMIDES AND THEIR USE FOR REDUCING LEVELS OF TNF$g(a)

1995
- 1995-10-06 US US08/539,879 patent/US5658940A/en not_active Expired - Lifetime
1996
- 1996-10-04 CA CA002233975A patent/CA2233975C/en not_active Expired - Fee Related
- 1996-10-04 RU RU98108602/04A patent/RU2176242C2/ru not_active IP Right Cessation
- 1996-10-04 AT AT96936155T patent/ATE248145T1/de not_active IP Right Cessation
- 1996-10-04 CZ CZ981053A patent/CZ105398A3/cs unknown
- 1996-10-04 AU AU73873/96A patent/AU723915B2/en not_active Ceased
- 1996-10-04 JP JP51442097A patent/JP3226546B2/ja not_active Expired - Fee Related
- 1996-10-04 PL PL96326063A patent/PL326063A1/xx unknown
- 1996-10-04 NZ NZ321001A patent/NZ321001A/en not_active IP Right Cessation
- 1996-10-04 KR KR1019980702531A patent/KR100345826B1/ko not_active Expired - Fee Related
- 1996-10-04 EP EP96936155A patent/EP0862552B1/de not_active Expired - Lifetime
- 1996-10-04 HU HU9902034A patent/HUP9902034A3/hu unknown
- 1996-10-04 WO PCT/US1996/015864 patent/WO1997012859A1/en not_active Ceased
- 1996-10-04 ES ES96936155T patent/ES2206600T3/es not_active Expired - Lifetime
- 1996-10-04 PT PT96936155T patent/PT862552E/pt unknown
- 1996-10-04 DE DE69629716T patent/DE69629716T2/de not_active Expired - Lifetime
- 1996-10-04 SK SK446-98A patent/SK44698A3/sk unknown
1998
- 1998-04-03 FI FI980776A patent/FI119690B/fi active IP Right Grant

Also Published As

Publication number	Publication date
NZ321001A (en)	2001-03-30
JP3226546B2 (ja)	2001-11-05
CA2233975C (en)	2005-12-06
RU2176242C2 (ru)	2001-11-27
HUP9902034A2 (hu)	1999-11-29
CA2233975A1 (en)	1997-04-10
HUP9902034A3 (en)	2001-01-29
JPH11513387A (ja)	1999-11-16
WO1997012859A1 (en)	1997-04-10
DE69629716D1 (en)	2003-10-02
DE69629716T2 (de)	2004-07-08
US5658940A (en)	1997-08-19
KR19990064052A (ko)	1999-07-26
PL326063A1 (en)	1998-08-17
FI980776L (fi)	1998-06-05
EP0862552B1 (de)	2003-08-27
ES2206600T3 (es)	2004-05-16
FI980776A0 (fi)	1998-04-03
HK1017885A1 (en)	1999-12-03
KR100345826B1 (ko)	2002-11-18
EP0862552A1 (de)	1998-09-09
FI119690B (fi)	2009-02-13
AU723915B2 (en)	2000-09-07
SK44698A3 (en)	1998-09-09
PT862552E (pt)	2003-12-31
CZ105398A3 (cs)	1998-07-15
AU7387396A (en)	1997-04-28

Legal Events

Date

Code

Title

Description

2004-05-15

UEP

Publication of translation of european patent specification

Ref document number: 0862552

Country of ref document: EP

2011-07-15

REN

Ceased due to non-payment of the annual fee

Publication	Publication Date	Title
FI980776A0 (fi)	1998-04-03	Sukkinimidi ja maleimidi sytokiini-inhibiittoreita
ATE337301T1 (de)	2006-09-15	Substituierte imide als tnf inhibitoren
DK0851857T3 (da)	2004-06-21	Inhibitorer af tumornekrosefaktor-alpha
DK0800505T3 (da)	2001-12-27	Hidtil ukendte immunterapeutiske arylamider
NO20013982D0 (no)	2001-08-16	Substituerte 1-OXO- og 1,3-dioxoisoindoliner og deres bruk i farmasoytiske forbindelser for redusering av betennelsescytokinenivaer
ATE244713T1 (de)	2003-07-15	Substituierte indazolderivate und ihre verwendung als inhibitoren des phosphodiesterase (pde) typs 4 und des tumor-necrosin-factors (tnf)
WO1995001348A3 (en)	1995-03-09	Imides as inhibitors of tnp alpha
NO996529D0 (no)	1999-12-28	Substituerte alkanohydroksamsyrer og metode for reduksjon av TNF<alfa>-nivåer
DK0918746T3 (da)	2003-08-04	Immunterapeutiske midler og deres anvendelse til reduktion af cytokinniveauer
WO1998024763A3 (en)	1998-08-06	Immunotherapeutic imides/amides as pde iv and tnf inhibitors
DE69732966D1 (de)	2005-05-12	Substituierte indazolderivate und ihre verwendung als inhibitoren des phosphodiesterase (pde) des typs iv und der produktion des tumor nekrosis faktors (tnf)
NO984343D0 (no)	1998-09-18	Preparat inneholdende en kombinasjon av 5-metylisoksazol-4-karboksylsyre-(4-trifluormetyl)-anilid og N-(4-trifluor-metylfenyl)2-cyano-3-hydroksykrotin
NO992337D0 (no)	1999-05-14	Bicykliske arylkarboksamider og deres terapeutiske anvendelse
DK0797437T3 (da)	2001-06-05	Immunterapeutiske imider/amider samt anvendelse deraf til at reducere niveauer af TNFalfa
DK218083D0 (da)	1983-05-16	Aminoalkadien-derivater, deres fremstilling og anvendelse
NO171982C (no)	1993-05-26	Analogifremgangsmaate for fremstilling av nye terapeutisk aktive s-adenosylmethionindecarboxylase-inhibitorer, og mellomprodukter derfor
DK343283A (da)	1984-05-04	Fremgangsmaade til fremstilling af 5-substituerede trans-dl-octahydropyrazolo(3,4-g)quinoliner og mellemprodukt til brug ved fremgangsmaaden
FI850491L (fi)	1985-08-08	Som analgetiska och anti-inflammatoriska aemnen verkande 1,3-disubstituerade 2-oxindoler.
NO991072D0 (no)	1999-03-04	Intermediater for fremstilling av HIV-protease inhibitorer og fremgangsmÕter for fremstilling av HIV-protease inhibitorer